BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33764904)

  • 21. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
    Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
    J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
    Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
    Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer.
    Kumari N; Singh RK; Mishra SK; L R; Mohindra S; Krishnani N
    Pathol Res Pract; 2021 Jan; 217():153309. PubMed ID: 33341547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants.
    Earl J; Galindo-Pumariño C; Encinas J; Barreto E; Castillo ME; Pachón V; Ferreiro R; Rodríguez-Garrote M; González-Martínez S; Ramon Y Cajal T; Diaz LR; Chirivella-Gonzalez I; Rodriguez M; de Castro EM; García-Seisdedos D; Muñoz G; Rosa JMR; Marquez M; Malats N; Carrato A
    EBioMedicine; 2020 Mar; 53():102675. PubMed ID: 32113160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Familial Pancreatic Cancer and Surveillance of High-Risk Individuals.
    Matsubayashi H; Takaori K; Morizane C; Kiyozumi Y
    Gut Liver; 2019 Sep; 13(5):498-505. PubMed ID: 30917631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.
    Roberts NJ; Norris AL; Petersen GM; Bondy ML; Brand R; Gallinger S; Kurtz RC; Olson SH; Rustgi AK; Schwartz AG; Stoffel E; Syngal S; Zogopoulos G; Ali SZ; Axilbund J; Chaffee KG; Chen YC; Cote ML; Childs EJ; Douville C; Goes FS; Herman JM; Iacobuzio-Donahue C; Kramer M; Makohon-Moore A; McCombie RW; McMahon KW; Niknafs N; Parla J; Pirooznia M; Potash JB; Rhim AD; Smith AL; Wang Y; Wolfgang CL; Wood LD; Zandi PP; Goggins M; Karchin R; Eshleman JR; Papadopoulos N; Kinzler KW; Vogelstein B; Hruban RH; Klein AP
    Cancer Discov; 2016 Feb; 6(2):166-75. PubMed ID: 26658419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families.
    Bartsch DK; Langer P; Habbe N; Matthäi E; Chaloupka B; Sina M; Hahn SA; Slater EP
    Clin Genet; 2010 Apr; 77(4):333-41. PubMed ID: 20041885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history.
    Chaffee KG; Oberg AL; McWilliams RR; Majithia N; Allen BA; Kidd J; Singh N; Hartman AR; Wenstrup RJ; Petersen GM
    Genet Med; 2018 Jan; 20(1):119-127. PubMed ID: 28726808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants.
    Roberts NJ; Grant RC; Gallinger S; Klein AP;
    Genes Chromosomes Cancer; 2021 Aug; 60(8):559-564. PubMed ID: 33724601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.
    Ghiorzo P; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bernard L; Bonelli L; Borgonovo G; Bruno W; De Cian F; Decensi A; Filauro M; Faravelli F; Gozza A; Gargiulo S; Mariette F; Nasti S; Pastorino L; Queirolo P; Savarino V; Varesco L; Scarrà GB;
    J Med Genet; 2012 Mar; 49(3):164-70. PubMed ID: 22368299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exome sequencing and digital PCR analyses reveal novel mutated genes related to the metastasis of pancreatic ductal adenocarcinoma.
    Zhou B; Irwanto A; Guo YM; Bei JX; Wu Q; Chen G; Zhang TP; Lei JJ; Feng QS; Chen LZ; Liu J; Zhao YP
    Cancer Biol Ther; 2012 Aug; 13(10):871-9. PubMed ID: 22797009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pancreatic acinar cell carcinoma is associated with
    Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
    Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.
    Murphy KM; Brune KA; Griffin C; Sollenberger JE; Petersen GM; Bansal R; Hruban RH; Kern SE
    Cancer Res; 2002 Jul; 62(13):3789-93. PubMed ID: 12097290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PALB2 mutations in European familial pancreatic cancer families.
    Slater EP; Langer P; Niemczyk E; Strauch K; Butler J; Habbe N; Neoptolemos JP; Greenhalf W; Bartsch DK
    Clin Genet; 2010 Nov; 78(5):490-4. PubMed ID: 20412113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families.
    Slater EP; Langer P; Fendrich V; Habbe N; Chaloupka B; Matthäi E; Sina M; Hahn SA; Bartsch DK
    Fam Cancer; 2010 Sep; 9(3):335-43. PubMed ID: 20195775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hereditary vs Familial Pancreatic Cancer: Associated Genetic Syndromes and Clinical Perspective.
    Copur MS; Talmon GA; Wedel W; Hart JD; Merani S; Vargasi LM
    Oncology (Williston Park); 2020 Jun; 34(6):196-201. PubMed ID: 32609864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice.
    Mohindroo C; De Jesus-Acosta A; Yurgelun MB; Maitra A; Mork M; McAllister F
    Surg Pathol Clin; 2022 Sep; 15(3):491-502. PubMed ID: 36049831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the 4q32-34 locus in European familial pancreatic cancer.
    Earl J; Yan L; Vitone LJ; Risk J; Kemp SJ; McFaul C; Neoptolemos JP; Greenhalf W; ; Kress R; Sina-Frey M; Hahn SA; Rieder H; Bartsch DK;
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1948-55. PubMed ID: 17035404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
    Peters ML; Tseng JF; Miksad RA
    Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.